Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.

ABSTRACT:

Background and objective

Although multiple clinical trials have demonstrated that neoadjuvant immune checkpoint inhibitors combined with gemcitabine plus cisplatin achieve promising pathological complete response (pCR) rates in muscle-invasive bladder cancer patients, these studies generally excluded those with lymph node metastasis. This study aims to evaluate the efficacy and prognostic outcomes of neoadjuvant tislelizumab combined with gemcitabine plus cisplatin, followed by consolidative radical cystectomy (RC), in patients with clinically lymph node-positive bladder cancer.

Methods

In this prospective study (NCT04570410), patients with cT2-4N1-3M0 bladder cancer were enrolled. The treatment regimen consisted of tislelizumab (200 mg on day 8), gemcitabine (1000 mg/m

SUBMITTER: Zhuang J 

PROVIDER: S-EPMC12719189 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature